A combined phase II/III, observer blind, randomized, multi center study to evaluate safety, tolerability and immunogenicity of trivalent subunit influenza vaccines [influenza vrius vaccine], produced either in mammalian cell culture or in embryonated hen eggs, in healthy children and adolescents

Trial Profile

A combined phase II/III, observer blind, randomized, multi center study to evaluate safety, tolerability and immunogenicity of trivalent subunit influenza vaccines [influenza vrius vaccine], produced either in mammalian cell culture or in embryonated hen eggs, in healthy children and adolescents

Completed
Phase of Trial: Phase II/III

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Influenza vaccine (Optaflu) (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 28 Apr 2015 Pooled analysis safety and tolerability results presented at the 2015 Annual Meeting of the Pediatric Academic Societies.
    • 25 Mar 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
    • 15 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top